Our News & Updates

Press Releases, Psychedelics

XPhyto Announces Psychedelic Pharmaceutical Production Agreement

Feb 3, 2021

Vancouver, Canada (February 3, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that XPhyto Laboratories...

Continue Reading

Drug Delivery, Press Releases

XPhyto Announces Drug Formulation Strategy And 2021 Milestones

Jan 28, 2021

Construction of commercial drug manufacturing facility in GermanyFour clinical studies in neurological indications in 2021Development of oral biosensor and contract development & manufacturingPsychedelic transdermal and...

Continue Reading

Press Releases

XPhyto Announces Business Strategy And Milestones For 2021

Jan 18, 2021

Commercialization of rapid COVID-19 PCR testClinical validation of transdermal and sublingual drug formulationsPsychedelic API production, drug formulation and clinical integration Vancouver, Canada (January 18, 2021)...

Continue Reading

Diagnostics, Press Releases

XPhyto Completes Successful SARS-COV-2 RT-PCR Diagnostic Test Kit Validation

Dec 17, 2020

Vancouver, Canada (December 17, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), a next-generation bioscience accelerator, and its exclusive...

Continue Reading

Press Releases, Psychedelics

Exclusive Psychedelic Drug Development Agreement Secured

Nov 9, 2020

Psilocybin, mescaline, LSD, MDMA, DMT and other psychedelic compounds added to exclusive dealing agreement for the development of psychedelic-based therapeutics Vancouver, Canada (November 09, 2020)...

Continue Reading

Press Releases

XPhyto Appoints European Healthcare Executive To Board Of Directors

Nov 4, 2020

Experienced pharma executive and consultant Per S. Thoresen joins boardAdvisory engagement with CorpCann AS strengthens Europe-focused strategy Vancouver, Canada (November 04, 2020) - XPhyto Therapeutics...

Continue Reading

Press Releases, Psychedelics

XPhyto Engages German Partner For Development Of Psilocybin API Production

Nov 3, 2020

Research agreement to investigate the feasibility of a proprietary biotechnology process for the industrial production of psilocybin APIPsilocybin is designated by the FDA as a...

Continue Reading

Diagnostics, Press Releases

XPhyto Announces RT-PCR Test For Point-Of-Care COVID-19 Detection

Oct 28, 2020

25-minute RT-PCR lab test to complement 15-minute rapid testEuropean market launch of both COVID-19 tests planned for Q1 2021 Vancouver, Canada (October 28, 2020) -...

Continue Reading

Drug Delivery, Press Releases

Update On Contract Drug Delivery Programs

Oct 19, 2020

Vancouver, Canada (October 19, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), a next-generation bioscience company, is pleased to...

Continue Reading

Drug Delivery, Press Releases

Update On Oral Thin Film Drug Delivery Programs

Sep 22, 2020

Vancouver, Canada (September 22, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), a next-generation bioscience company, is pleased to...

Continue Reading

Diagnostics, Press Releases

Update On COVID-19 Rapid Test Commercialization

Sep 8, 2020

Vancouver, Canada (September 8, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), a next generation bioscience company, is pleased...

Continue Reading

Drug Delivery, Press Releases

XPhyto Provides Update On Parkinsons’ Transdermal Patch

Aug 25, 2020

Vancouver, Canada (August 25, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), a next generation bioscience company, is pleased...

Continue Reading